|
Market Closed -
Bombay S.E.
13:24:04 11/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 1,842.00 INR | -1.18% |
|
-3.00% | +7.11% |
| 09-09 | Sun Pharma Sets Up Global Treasury Center in India's GIFT City | MT |
| 09-09 | Sun Pharma Assigned Baa1, BBB+ Ratings by Moody's, S&P | MT |
| Market Cap | 4,415B 46.21B 39.82B 37.7B 34.17B 64.11B 64.43B 448B 172B 2,246B 174B 170B 7,097B | P/E 2027 * |
34x | P/E 2028 * | 28.7x |
|---|---|---|---|---|---|
| Enterprise Value | 4,144B 43.38B 37.37B 35.39B 32.08B 60.18B 60.48B 420B 162B 2,108B 163B 159B 6,662B | EV / Sales 2027 * |
6.37x | EV / Sales 2028 * | 5.59x |
| Free-Float |
44.39% | Yield 2027 * |
0.93% | Yield 2028 * | 1.08% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript : Sun Pharmaceutical Industries Ltd.
| 1 day | -1.18% | ||
| 1 week | -3.00% | ||
| Current month | -5.83% | ||
| 1 month | -4.81% | ||
| 3 months | +1.92% | ||
| 6 months | +0.93% | ||
| Current year | +7.11% |
| 1 week | 1,833.9 |  | 1,907.35 |
| 1 month | 1,833.9 | | 1,964.85 |
| Current year | 1,583.6 | | 2,047.55 |
| 1 year | 1,547.25 | | 2,047.55 |
| 3 years | 1,069 | | 2,047.55 |
| 5 years | 733.95 | | 2,047.55 |
| 10 years | 315.2 | | 2,047.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.18% | -3.00% | - | - | 46.21B | |
| -1.13% | -3.11% | +13.82% | +60.66% | 46.21B | |
| -1.13% | -5.78% | +33.26% | +108.13% | 38.78B | |
| +0.12% | -0.08% | +7.12% | +78.27% | 11.68B | |
| -0.53% | -1.37% | -13.25% | +10.18% | 11.55B | |
| -0.38% | -2.26% | +18.18% | +139.63% | 9.14B | |
| +0.32% | -2.26% | +23.08% | +34.73% | 7.3B | |
| +0.17% | -0.74% | +13.44% | +197.13% | 7.15B | |
| -1.00% | -5.25% | +34.34% | -19.63% | 7.1B | |
| -3.13% | -4.30% | -44.88% | +11.66% | 4.97B | |
| Average | -0.79% | -2.59% | +9.46% | +68.97% | 15.99B | |
| Weighted average by Cap. | -0.94% | -3.27% | +16.06% | +75.66% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.81B 5.87B 5.56B 5.04B 9.45B 9.5B 66.03B 25.39B 331B 25.59B 25.03B 1,047B | 729B 7.63B 6.57B 6.23B 5.64B 10.59B 10.64B 73.94B 28.43B 371B 28.66B 28.03B 1,172B |
| Net income | 130B 1.36B 1.17B 1.11B 1B 1.88B 1.89B 13.15B 5.06B 65.97B 5.1B 4.99B 208B | 154B 1.61B 1.39B 1.31B 1.19B 2.23B 2.24B 15.58B 5.99B 78.17B 6.04B 5.91B 247B |
| Net Debt | -271B -2.83B -2.44B -2.31B -2.09B -3.93B -3.95B -27.45B -10.56B -138B -10.64B -10.41B -435B | -338B -3.54B -3.05B -2.89B -2.62B -4.91B -4.94B -34.32B -13.2B -172B -13.3B -13.01B -544B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | ₹1,842.00 | -1.18% | 95,615 |
| 10/09/26 | ₹1,864.00 | -0.24% | 74,021 |
| 09/09/26 | ₹1,868.50 | -0.67% | 235,131 |
| 08/09/26 | ₹1,881.10 | -0.98% | 287,683 |
| 07/09/26 | ₹1,899.80 | +0.04% | 77,426 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
